) are higher on the session by 0.33%, currently trading at $88.38. The ETF has been moving largely higher over the past four months, jumping off of a recent low at $75.20. First resistance is at $92.65. Options traders are bellying up to the biotech bar today. A short while ago the November $88.00 call was purchased 2,000 times, on the offer, for $1.95 on open interest of 2,127 contracts. Overall call volume is now running at 4.63x the daily average, with 100% of all calls traded being purchases on the offer. The iShares NASDAQ Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance of the Nasdaq Biotechnology index. The fund uses the process of representative sampling, holding securities that have a similar investment profile to its index. The fund normally invests at least 90% of assets in the securities of the index which contains securities of NASDAQ(R) listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals. The fund may hold up to 10% of assets in securities that are not included in the index. It is nondiversified. It is non-diversified.